<?xml version="1.0" encoding="UTF-8"?>
<p>The physiological function of aSyn is affected by glycation in several ways: It was shown both in human cell lines and in animal models that glycated aSyn is more prone to oligomerization (
 <xref ref-type="fig" rid="jpd-8-jpd171285-g002">Fig.Â 2</xref>) [
 <xref rid="ref074" ref-type="bibr">74, 76, 77</xref>]. Furthermore, studies in a PD cell models revealed that glycated aSyn displays reduced mono-ubiquitination, proteasome- and autophagy-lysosome-mediated degradation [
 <xref rid="ref074" ref-type="bibr">74</xref>]. In addition, MGO-treatment was shown to lead to reduced aSyn release and impaired binding to lipid membranes, further contributing to accumulation of aSyn inside cells [
 <xref rid="ref074" ref-type="bibr">74</xref>]. Interestingly, aSyn physiology is not just altered directly by glycating agents. Actually, the presence of AGEs produced, for example, from bovine serum albumin, induces the cross-linking of aSyn [
 <xref rid="ref078" ref-type="bibr">78</xref>]. Despite progress made on unrevealing the complex effects of glycating agents on aSyn physiology and pathology, a number of questions remain.
</p>
